U.S. markets close in 5 hours 14 minutes

Forma Therapeutics Holdings, Inc. (FMTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.30-2.03 (-7.17%)
As of 10:46AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close28.33
Open28.12
Bid26.17 x 800
Ask26.49 x 1000
Day's Range26.02 - 28.51
52 Week Range22.51 - 56.33
Volume130,325
Avg. Volume505,781
Market Cap1.312B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Benzinga

      Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study

      Forma Therapeutics Holdings Inc (NASDAQ: FMTX) has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202, a pyruvate kinase R activator. The 600 mg high-dose cohort featured fewer hemoglobin responders than the 300-mg arm, but FT-4202 showed a similar safety and tolerability profile as the 300 mg cohort, despite the doubling of the dose. Six of the seven patients who received the 300-mg dose of FT-4202 had hemoglobin increases of 1.0 g/dl or greater from baseline. Four of the seven patients taking 600 mg had hemoglobin increases of 1.0 g/dl or greater from baseline. The 600 mg dose fared numerically worse on other endpoints, too, lowering LDH in four patients compared to the six people positively affected by the 300 mg dose. The median change in LDH and reticulocytes, respectively hematologic and hemolytic biomarkers, was also numerically lower at 600 mg. Forma will conduct an open-label extension study giving a 400-mg dose for 12 weeks. Forma is also using a 400-mg dose and a 200-mg dose in its Phase 2/3 clinical trial. The primary endpoints of phase 2/3 are hemoglobin response at Week 24 and vaso-occlusive crisis rate across the 52-week blinded treatment period. Unblinded 600 mg cohort data will be reported at an upcoming medical conference in Summer 2021, in addition to initial results from the ongoing open-label extension. Price Action: FMTX shares are trading 8.1% lower at $23.13 in market hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaTiziana To Treat Multiple Sclerosis Patient With Nasal Administration of ForalumabMonopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update
      Business Wire

      Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update

      Forma Therapeutics reports financial results from Q4 and full year 2020, as well as business updates.

    • Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study
      Business Wire

      Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study

      Forma Therapeutics announces positive data from the 600 mg cohort in the Phase 1 trial of FT-4202 in sickle cell patients.